Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01321554




Registration number
NCT01321554
Ethics application status
Date submitted
10/03/2011
Date registered
23/03/2011
Date last updated
22/06/2023

Titles & IDs
Public title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
Scientific title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Secondary ID [1] 0 0
2010-023783-41
Secondary ID [2] 0 0
E7080-G000-303
Universal Trial Number (UTN)
Trial acronym
SELECT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Thyroid Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Thyroid
Metabolic and Endocrine 0 0 0 0
Other endocrine disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Lenvatinib
Treatment: Drugs - Placebo
Treatment: Drugs - Lenvatinib

Experimental: Lenvatinib (Randomization Phase) - Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.

Placebo comparator: Placebo (Randomization Phase) - Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.

Experimental: Lenvatinib 24 mg (OOL Lenvatinib Treatment Period) - Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.

Experimental: Lenvatinib 20 mg (OOL Lenvatinib Treatment Period) - Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.


Treatment: Drugs: Lenvatinib
Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.

Treatment: Drugs: Placebo
Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.

Treatment: Drugs: Lenvatinib
Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.

The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS)
Timepoint [1] 0 0
Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
Secondary outcome [1] 0 0
Overall Response Rate (ORR)
Timepoint [1] 0 0
Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Date of randomization until date of death from any cause, assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years
Secondary outcome [3] 0 0
Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve
Timepoint [3] 0 0
Cycle 1 Days 1 and 15: 0-10 hours postdose; Cycle 2 Day 1: 0-12 hour postdose

Eligibility
Key inclusion criteria
Inclusion criteria:

1. Histologically or cytologically confirmed diagnosis of one of the following DTC subtypes: Papillary thyroid cancer (PTC) or follicular thyroid cancer (FTC).
2. Measurable disease according to (RECIST 1.1) and confirmed by central radiographic review.
3. 131 I-refractory/resistant disease.
4. Evidence of disease progression within 12 months prior to signing informed consent (+1 month screening window).
5. Prior treatment with 0 or 1 vascular endothelial growth-factor (VEGF) or vascular endothelial growth-factor receptors (VEGFR) targeted therapy.
6. Adequate renal, liver, bone marrow, and blood coagulation function, as defined in the protocol.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria:

1. Anaplastic or medullary carcinoma of the thyroid
2. 2 or more prior VEGF/ VEGFR-targeted therapies
3. Received any anticancer treatment within 21 days or any investigational agent within 30 days prior to the first dose of study drug.

Inclusion criteria for OOL Lenvatinib Treatment Period :

Participants were eligible for lenvatinib treatment in the OOL Lenvatinib Treatment Period if the met the following criteria:

1. Placebo-treated participants in the Randomization Phase who had progressive disease (PD) confirmed by IIR, and who requested treatment with lenvatinib.
2. Participants who continued to satisfy specified inclusion and exclusion criteria as presented in the study protocol.
3. Participants with maximum interval between the day of confirmation of PD by IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period of less than or equal to 3 months.
4. No systemic anticancer treatment during the interval between the day of confirmation of PD by the IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/03/2011
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/03/2019
Sample size
Target
Accrual to date
Final
392
Recruitment in Australia
Recruitment state(s)
NSW,QLD,TAS,VIC
Recruitment hospital [1] 0 0
Facility 1 - Saint Leonards
Recruitment hospital [2] 0 0
Facility 1 - Herston
Recruitment hospital [3] 0 0
Facility 1 - Hobart
Recruitment hospital [4] 0 0
Facility 1 - Melbourne
Recruitment hospital [5] 0 0
Facility 1 - Heidelberg
Recruitment postcode(s) [1] 0 0
- Saint Leonards
Recruitment postcode(s) [2] 0 0
- Herston
Recruitment postcode(s) [3] 0 0
- Hobart
Recruitment postcode(s) [4] 0 0
- Melbourne
Recruitment postcode(s) [5] 0 0
- Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New Hampshire
Country [15] 0 0
United States of America
State/province [15] 0 0
New Jersey
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Washington
Country [22] 0 0
United States of America
State/province [22] 0 0
West Virginia
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Argentina
State/province [24] 0 0
Rosario
Country [25] 0 0
Argentina
State/province [25] 0 0
San Salvador de Jujuy
Country [26] 0 0
Argentina
State/province [26] 0 0
Tucuman
Country [27] 0 0
Austria
State/province [27] 0 0
Wien
Country [28] 0 0
Belgium
State/province [28] 0 0
Bruxelles
Country [29] 0 0
Belgium
State/province [29] 0 0
Edegem
Country [30] 0 0
Belgium
State/province [30] 0 0
Namur
Country [31] 0 0
Brazil
State/province [31] 0 0
Brasilia
Country [32] 0 0
Brazil
State/province [32] 0 0
Joinville
Country [33] 0 0
Brazil
State/province [33] 0 0
Novo Hamburgo
Country [34] 0 0
Brazil
State/province [34] 0 0
Rio de Janeiro
Country [35] 0 0
Brazil
State/province [35] 0 0
Salvador
Country [36] 0 0
Brazil
State/province [36] 0 0
Sao Paulo
Country [37] 0 0
Canada
State/province [37] 0 0
Ontario
Country [38] 0 0
Canada
State/province [38] 0 0
Quebec
Country [39] 0 0
Chile
State/province [39] 0 0
Santiago
Country [40] 0 0
Chile
State/province [40] 0 0
Temuco
Country [41] 0 0
Chile
State/province [41] 0 0
Vina del Mar
Country [42] 0 0
Czechia
State/province [42] 0 0
Olomouc
Country [43] 0 0
Denmark
State/province [43] 0 0
Odense
Country [44] 0 0
France
State/province [44] 0 0
Angers
Country [45] 0 0
France
State/province [45] 0 0
Bordeaux
Country [46] 0 0
France
State/province [46] 0 0
Caen
Country [47] 0 0
France
State/province [47] 0 0
Clermont-Ferrand
Country [48] 0 0
France
State/province [48] 0 0
Dijon
Country [49] 0 0
France
State/province [49] 0 0
Lille
Country [50] 0 0
France
State/province [50] 0 0
Lyon
Country [51] 0 0
France
State/province [51] 0 0
Marseille
Country [52] 0 0
France
State/province [52] 0 0
Nice
Country [53] 0 0
France
State/province [53] 0 0
Paris
Country [54] 0 0
France
State/province [54] 0 0
Strasbourg
Country [55] 0 0
France
State/province [55] 0 0
Vandoeuvre Les Nancy
Country [56] 0 0
France
State/province [56] 0 0
Villejuif
Country [57] 0 0
Germany
State/province [57] 0 0
Essen
Country [58] 0 0
Germany
State/province [58] 0 0
Hannover
Country [59] 0 0
Germany
State/province [59] 0 0
Leipzig
Country [60] 0 0
Germany
State/province [60] 0 0
Mainz
Country [61] 0 0
Germany
State/province [61] 0 0
Munchen
Country [62] 0 0
Germany
State/province [62] 0 0
Tubingen
Country [63] 0 0
Germany
State/province [63] 0 0
Wurzburg
Country [64] 0 0
Italy
State/province [64] 0 0
Catania
Country [65] 0 0
Italy
State/province [65] 0 0
Livorno
Country [66] 0 0
Italy
State/province [66] 0 0
Milano
Country [67] 0 0
Italy
State/province [67] 0 0
Monserrato
Country [68] 0 0
Italy
State/province [68] 0 0
Napoli
Country [69] 0 0
Italy
State/province [69] 0 0
Padova
Country [70] 0 0
Italy
State/province [70] 0 0
Pisa
Country [71] 0 0
Italy
State/province [71] 0 0
Roma
Country [72] 0 0
Italy
State/province [72] 0 0
Rozzano
Country [73] 0 0
Italy
State/province [73] 0 0
Torino
Country [74] 0 0
Italy
State/province [74] 0 0
Viagrande
Country [75] 0 0
Japan
State/province [75] 0 0
Aichi
Country [76] 0 0
Japan
State/province [76] 0 0
Chiba
Country [77] 0 0
Japan
State/province [77] 0 0
Fukui
Country [78] 0 0
Japan
State/province [78] 0 0
Hyogo
Country [79] 0 0
Japan
State/province [79] 0 0
Tokyo
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Daejeon
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Gyeonggi-do
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Seoul
Country [83] 0 0
Korea, Republic of
State/province [83] 0 0
Uijeongbu
Country [84] 0 0
Poland
State/province [84] 0 0
Gliwice
Country [85] 0 0
Poland
State/province [85] 0 0
Kielce
Country [86] 0 0
Poland
State/province [86] 0 0
Poznan
Country [87] 0 0
Portugal
State/province [87] 0 0
Lisbon
Country [88] 0 0
Portugal
State/province [88] 0 0
Porto
Country [89] 0 0
Romania
State/province [89] 0 0
Bucharest
Country [90] 0 0
Romania
State/province [90] 0 0
Cluj-Napoca
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Krasnodar
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Kursk
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Obninsk
Country [94] 0 0
Russian Federation
State/province [94] 0 0
Ufa
Country [95] 0 0
Spain
State/province [95] 0 0
Andalucia
Country [96] 0 0
Spain
State/province [96] 0 0
Cataluna
Country [97] 0 0
Spain
State/province [97] 0 0
Galicia
Country [98] 0 0
Spain
State/province [98] 0 0
Barcelona
Country [99] 0 0
Spain
State/province [99] 0 0
L'Hospitalet de Llobregat
Country [100] 0 0
Spain
State/province [100] 0 0
Madrid
Country [101] 0 0
Sweden
State/province [101] 0 0
Goteborg
Country [102] 0 0
Sweden
State/province [102] 0 0
Lund
Country [103] 0 0
Sweden
State/province [103] 0 0
Stockholm
Country [104] 0 0
Thailand
State/province [104] 0 0
Bangkok
Country [105] 0 0
Thailand
State/province [105] 0 0
Chiang Mai
Country [106] 0 0
Thailand
State/province [106] 0 0
Khon Kaen
Country [107] 0 0
Thailand
State/province [107] 0 0
Pathumwan
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Aberdeen
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Glasgow
Country [110] 0 0
United Kingdom
State/province [110] 0 0
London
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Manchester
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Sheffield
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Sutton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eisai Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01321554